Nelson Advisors featured in BioXconomy, the flagship publication for Informa Life Sciences
NA
Last week, BioXconomy reported on Novartis’ announcement at the conference that detailed two licensing agreements with SciNeuro Pharmaceuticals and Zonsen PepLib. Sanofi also made big plays at the start of the month, signing a deal with Earendil Labs worth $2.56 billion to lead the development and commercialization of bispecific antibodies. The French pharmaceutical company also acquired Dynavax for $2.2 billion, along with its immunization drug candidates.
A report by Nelson Advisors noted that while large pharmaceutical companies remain active in M&A scouting, many are taking a more disciplined approach to favoring targeted acquisitions over large-scale transactions.
“The strategy involves the systematic acquisition of smaller, early- to mid-stage innovative companies or assets, primarily to fortify drug pipelines, mitigate the impact of impending patent expirations, and integrate crucial new capabilities.”
Source: https://www.bioxconomy.com/partnering/rumor-has-it-sanofi-secretly-bids-for-retinal-drug-developer
About BioXonomy
BioXconomy, owned by Informa, engages the industry, builds community, and connects life sciences professionals to current, credible information, products and services relevant to their business. As the official media partner for Informa Life Sciences flagship events including BIO-Europe and LSX World Congress, TIDES US and RNA Leaders, ACCESS US and Pharma Forum, BioXconomy offers our audiences exclusive event-based insights, updated news and features, and interactive media.